

REMARKS

Claims 11, 12, and 15, are pending. Claims 11, 12, and 15, are rejected. Claims 11, 12, and 15, are amended. Support for amended Claims 11, 12, and 15, can be found, e.g., in Claims 11, 12, and 15, as filed, and, e.g., on page 58, lines 20-36, of the Specification. Applicants believe that no new matter is added by way of amendment.

I. Rejections of Claims 11, 12, and 15, under 35 U.S.C. §112, Second Paragraph.

The Examiner rejected Claims 11, 12, and 15, under 35 U.S.C. §112, second paragraph on the basis of the recitation of "antibody binding site." Applicants submit that amended Claims 11, 12, and 15, do not contain the basis for this rejection.

Applicants submit that the rejection of Claims 11, 12, and 15, under 35 U.S.C. §112, second paragraph, is overcome. Withdrawal of the rejection under 35 U.S.C. §112, second paragraph is respectfully requested.

Conclusion

Applicants' current response is believed to be a complete reply to all the outstanding issues of the latest Office action. Further, the present response is a bona fide effort to place the application in condition for allowance or in better form for appeal. Accordingly, Applicants respectfully request reconsideration and passage of the amended claims to allowance at the earliest possible convenience.


Applicants believe that no fees are due with this communication. Should this not be the case, the Commissioner is hereby authorized to debit any charges or refund any overpayments to DNAX Deposit Account No. 04-1239.

If the Examiner believes that a telephonic conference would aid the prosecution of this case in any way, please call the undersigned.

Respectfully submitted,

Dated: April 16, 2003

By:


Sheela Mohan-Peterson
Attorney for Applicants
Reg. No. 41, 201

DNAX Research, Inc.
901 California Avenue
Palo Alto, California 94304-1104
Tel: 650-496-6400
Fax: 650-496-1200